← All trials
NCT03140358
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 2, 2017
- Primary completion
- May 2, 2021
- Completion date
- May 2, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 570
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Singapore National Eye CentreLead sponsor
- Singapore National Eye CentreOverall official - principal investigator
- Singapore National Eye CentreReponsible party - principal investigator
- Government of SingaporeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.